Contact
 

IAVI Statement in Response to MDP 301 Phase III Trial of a Vaginal Microbicide

The International AIDS Vaccine Initiative released a statement congratulating the partners involved in the MDP 301 Phase III clinical trial of a vaginal microbicide on the successful conduct of the largest microbicide trial completed to date. IAVI said the trial itself provided other achievements that will help advance microbicide development and HIV prevention research generally. Please see the below attachment for the full statement.

Global HIV Vaccine Enterprise, 64 Beaver Street, # 352, New York, NY 10004 | +1 212-461-3692 or toll free at +1-866-966-4483
All Content ©2005 - 2013 Global HIV Vaccine Enterprise   |   Terms of Use   |   Privacy Policy   |   Log In / My Account